ARDT

Platform and Strategic Position

• Ardent operates 30 hospitals and over 280 care sites, with markets growing 2-3x faster than the U.S. average; over the past two years, the company has added over 25 new urgent care and ASC facilities to expand access and drive volume growth.
• Strategic partnerships with Ensemble (revenue cycle) and Epic (clinical systems) form the backbone of the company's clinical and operational technology infrastructure, enabling standardization and efficiency.

Operational Efficiency (Impact Program)

• The multi-year Impact efficiency program has expanded its 2026 savings target twice, from an original $40 million to $55 million to over $70 million now, driven by structural streamlining and additional cost reduction initiatives.
• Labor cost control has delivered strong results: Salaries, Wages and Benefits (SWB) grew only 0.7% YoY, contract labor spend was reduced 42% YoY, dropping contract labor as a percentage of SWB to 2.2% from 3.8% YoY. Year-over-year professional fee growth slowed to 10.4% from 12.9% in Q1.
• Additional cost optimization work includes supply chain vendor consolidation, contract renegotiation, streamlining physician preference items, and rationalizing redundant IT applications.

Revenue and Growth Initiatives

• The company has adopted a data-driven approach to payer contracting, using price transparency data to lift under-market rates; a June 2026 key payer renewal is expected to add $5-$10 million in 2026 adjusted EBITDA not included in prior guidance.
• Growth is focused on high-value core service lines including cardiology, women's and children's, aligned with the Capacity IQ framework that matches demand to system-wide capacity and directs capital and physician recruitment to highest-return opportunities.
• Service line rationalization is underway: lower-margin procedures (ENT, ophthalmology) have been moved out of inpatient hospital settings to free capacity for higher-margin service lines.
• AI and virtual care are driving clinical efficiency: in first-launch markets Texas and Idaho, HelloCare AI virtual nurses completed 58% of discharges in June and reduced patient monitoring hours by 18%, improving capacity management.

Leadership and Cultural Priorities

• Current CEO priorities are sharper operational execution, reduced operational variation, KPI-driven executive decision making, and stronger accountability, with a focus on building a unified culture aligned to shared targets.

• Full year 2026 adjusted EBITDA guidance is maintained at $485-$535 million, despite a ~$25 million headwind from lower-than-expected volumes that is fully offset by $20-$30 million in incremental gains from payer recontracting and structural cost savings. Revenue is now biased toward the lower end of the prior $6.4-$6.7 billion range, due to sustained softer volume trends after April-May weakness.
• Q3 2026 adjusted EBITDA is expected to improve from Q2's $115 million and approach Q1 2026's $124 million level, as the incremental gains from Q2 initiatives will be at full run rate entering the quarter.
• The full-year $35 million projected headwind from exchange coverage loss is reaffirmed; actual trends through the first half are better than expected, with a material share of individuals losing exchange coverage moving to other forms of insurance rather than self-pay, and the $35 million projection retains built-in conservatism.
• The 2026 Impact program savings target is raised to at least $70 million, up from the prior $55 million, driven by $15-$20 million in incremental annual savings from recent structural streamlining that will be realized in full in 2026, with a $30-$35 million full annualized run-rate impact.

Ardent Health reports aggregated results for the entire system rather than separate product segments. Q2 2026 total revenue was $1.62 billion, adjusted EBITDA was $115 million. Key volume metrics: total surgeries declined 2.9% YoY, admissions declined 1% YoY; adjusted admissions increased 2.5% YoY, while net patient service revenue per adjusted admission decreased 3.9% YoY. By payer mix, exchange admissions declined 8% YoY with a corresponding increase in self-pay volumes. Operating cash flow for Q2 was $197 million, up from $117 million YoY; first half 2026 operating cash flow totaled $137 million, up 47% YoY. Capital expenditures for Q2 were $39 million, and $13 million in share repurchases were completed in the quarter.

• Persistent macroeconomic pressure has suppressed demand for higher-acuity procedures, particularly among patients with high-deductible health plans, leading to softer-than-expected volumes in April and May 2026 that have continued below original full-year expectations.
• Continued double-digit growth in health insurance premiums and deductibles could dampen elective procedure utilization for the remainder of 2026.
• Payer denial trends are dependent on unpredictable payer behavior, creating uncertainty around future revenue yield, though denial trends have remained stable through the first half of 2026.
• Further acceleration in exchange coverage loss could increase the self-pay headwind beyond the current $35 million projected impact.
• Payer contract negotiations can be contentious, and may require disruptive outreach to members to achieve fair rate adjustments, creating execution risk for the payer contracting strategy.

Q: How many additional markets have opportunity to lift outpatient rates to market levels, and what caused the steeper inpatient surgery decline seen in Q2?

A: The company sees rate adjustment opportunity across all markets, after breaking down silos between revenue integrity, revenue cycle management and contracting to implement a new data-driven, market-focused approach. The steeper inpatient decline was largely driven by procedures shifting from inpatient to outpatient after removal from the inpatient-only list, with a very modest net economic impact of $1-$2 million for the quarter.

Q: Is the June-July volume recovery broad-based, what volume trend is baked into H2 guidance, and is 2026 a low baseline for future growth?

A: The recovery was broad-based across all volume metrics. Guidance assumes H2 volumes will run at the Q2 average rather than the improved June-July run rate, as a prudent approach, and the company has already adjusted its cost structure to accommodate lower volumes. Management notes that care can't be deferred forever, creating pent-up demand potential, and is positioned to deliver results regardless of volume trends, with a strong top-of-funnel pipeline.

Q: What is the strategic rationale for service line rationalization, and what impact will it have on H2 surgical volumes?

A: A dedicated cross-functional Products and Services team uses Capacity IQ to review all assets and service lines, shifting lower-margin services out of acute care to free capacity for high-growth, higher-margin lines like cardiology and women's and children's. H2 surgical volumes are expected to remain at the Q2 low-single-digit decline level, as it takes time to wind down existing services and ramp up new lines, but management is confident the strategy will improve long-term margins.

Q: What is the updated strategy for joint ventures (JVs) versus outpatient growth and share repurchases, and how does this impact capital allocation?

A: The core three-part strategy (margin expansion via operational excellence, core market organic growth, disciplined M&A) remains unchanged; JV opportunities are still pursued, and existing JVs like UT Tyler are performing well and remain a focus. Capital allocation is balanced and opportunistic: the company retains a strong balance sheet to pursue opportunities, and will continue repurchasing shares as long as management sees underlying value dissociation, with $34 million remaining in the current repurchase authorization.